Literature DB >> 15537833

Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).

Sukhwinder S Lakhman1, Debashis Ghosh, Javier G Blanco.   

Abstract

Human carbonyl reductase (CBR) activity accounts for a significant fraction of the metabolism of endogenous and xenobiotic carbonyl compounds. It is possible that genetic polymorphisms in CBR1 and CBR3 are key for the wide interindividual variability in the disposition of CBR drug substrates. We pinpointed a single nucleotide polymorphism in CBR3 (CBR3 V244M) that encodes for a V244 to M244 change. Blacks showed a higher frequency of the M244 allele (q = 0.51, n = 49) than did whites (q = 0.31, n = 70; p = 0.003). In addition, DNA variation panels from 10 ethnic groups presented a wide range of CBR3 V244M genotype distributions. Kinetic experiments with the recombinant CBR3 protein variants and menadione revealed that CBR3 M244 has significantly higher V(max) than does CBR3 V244 (V(max) CBR3 M244 = 40.6 +/- 1.3 micromol/min x mg versus V(max) CBR3 V244 = 19.6 +/- 2.0 micromol/min x mg, p = 0.002). In contrast, both isoforms presented similar K(m) values (K(m) CBR3 M244 = 22.9 +/- 2.9 microM versus K(m) CBR3 V244 = 24.6 +/- 3.2 microM, p = 0.43). Assays with NADP(H) demonstrated a higher V(maxNADP(H)) (1.6-fold) and increased catalytic efficiency (V(maxNADP(H))/K(mNADP(H))) for CBR3 M244 compared with CBR3 V244 (p = 0.013). Comparative three-dimensional analyses based on the structure of the homologous porcine carbonyl reductase suggested that the V244M substitution is positioned in a region critical for interactions with the NADP(H) cofactor. These studies demonstrate that the common CBR3 V244M polymorphism encodes for CBR3 isoforms with distinctive enzymatic properties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537833     DOI: 10.1124/dmd.104.002006

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Doxorubicin pathways: pharmacodynamics and adverse effects.

Authors:  Caroline F Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

Review 2.  Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?

Authors:  Saro H Armenian; Smita Bhatia
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

3.  Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.

Authors:  Adolfo Quiñones-Lombraña; Daniel Ferguson; Rachael Hageman Blair; James L Kalabus; Almedina Redzematovic; Javier G Blanco
Journal:  Pharm Res       Date:  2014-02-22       Impact factor: 4.200

4.  Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Authors:  Javier G Blanco; Can-Lan Sun; Wendy Landier; Lu Chen; Diego Esparza-Duran; Wendy Leisenring; Allison Mays; Debra L Friedman; Jill P Ginsberg; Melissa M Hudson; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Doojduen Villaluna; Mary V Relling; Smita Bhatia
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

5.  Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.

Authors:  Daniel Bernstein; Paul Burridge
Journal:  Prog Pediatr Cardiol       Date:  2014-12-01

6.  Structural basis for substrate specificity in human monomeric carbonyl reductases.

Authors:  Ewa S Pilka; Frank H Niesen; Wen Hwa Lee; Yasser El-Hawari; James E Dunford; Grazyna Kochan; Vladimir Wsol; Hans-Joerg Martin; Edmund Maser; Udo Oppermann
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

7.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Authors:  J Bray; J Sludden; M J Griffin; M Cole; M Verrill; D Jamieson; A V Boddy
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

Review 8.  Long-term consequences of hematopoietic stem cell transplantation: current state of the science.

Authors:  K Scott Baker; Saro Armenian; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-24       Impact factor: 5.742

9.  Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).

Authors:  Vanessa Gonzalez-Covarrubias; James L Kalabus; Javier G Blanco
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

10.  Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1.

Authors:  Takeshi Miura; Toru Nishinaka; Tomoyuki Terada
Journal:  Mol Cell Biochem       Date:  2008-05-21       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.